Strayer, David R, Young, Diane, Mitchell, William M · PloS one · 2020 · DOI
This study tested a drug called rintatolimod in ME/CFS patients to see if it could improve their ability to exercise. The researchers found that patients who had been sick for 2-8 years responded much better to the drug than those who had been sick for less than 2 years or more than 8 years. Over half of the patients in the right disease duration window improved their exercise capacity by at least 25%, which also improved their quality of life.
This study suggests that disease duration is a critical factor determining which ME/CFS patients might benefit from rintatolimod, potentially explaining mixed results in previous trials and helping identify patients most likely to respond to this immune-modulating therapy. The findings may also have implications for post-COVID patients with persistent fatigue and cognitive impairment. Understanding patient stratification factors could improve future clinical trial design and treatment selection.
This post-hoc analysis does not prove that disease duration is the biological cause of differential treatment response—it is observational and hypothesis-generating rather than mechanistic. The study cannot establish why the 2-8 year window is optimal or whether similar patterns would apply to other ME/CFS treatments. Results require prospective validation in a new clinical trial with disease duration as a pre-specified stratification factor.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Strayer, David R, Young, Diane, & Mitchell, William M (2020). Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.. PloS one. https://doi.org/10.1371/journal.pone.0240403
BibTeX
@article{mecfsatlas-strayer-2020-effect-disease,
author = {Strayer, David R and Young, Diane and Mitchell, William M},
title = {Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.},
journal = {PloS one},
year = {2020},
doi = {10.1371/journal.pone.0240403},
note = {PubMed: 33119613},
url = {https://www.mecfsatlas.com/evidence/strayer-2020-effect-disease},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-29. https://www.mecfsatlas.com/evidence/strayer-2020-effect-disease
Contribute
Private, reviewed by a human. Not a public comment thread.